Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice

The four serotypes of dengue virus (DENV1–4) continue to pose a major public health threat. The first licenced dengue vaccine, which expresses the surface proteins of DENV1–4, has performed poorly in immunologically naïve individuals, sensitising them to antibody-enhanced dengue disease. DENV non-st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilken, Lucas, Stelz, Sonja, Agac, Ayse, Sutter, Gerd, Prajeeth, Chittappen Kandiyil, Rimmelzwaan, Guus F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140942/
https://www.ncbi.nlm.nih.gov/pubmed/37112626
http://dx.doi.org/10.3390/vaccines11040714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140942/
https://www.ncbi.nlm.nih.gov/pubmed/37112626
http://dx.doi.org/10.3390/vaccines11040714

Ejemplares similares